Stanley Laman Group Ltd. purchased a new position in shares of Edwards Lifesciences Corp (NYSE:EW) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,468 shares of the medical research company’s stock, valued at approximately $271,000.

Several other hedge funds also recently bought and sold shares of EW. Advisory Services Network LLC raised its position in Edwards Lifesciences by 0.4% during the second quarter. Advisory Services Network LLC now owns 14,932 shares of the medical research company’s stock valued at $2,759,000 after acquiring an additional 59 shares in the last quarter. Pendal Group Ltd raised its position in Edwards Lifesciences by 41.6% during the second quarter. Pendal Group Ltd now owns 3,982 shares of the medical research company’s stock valued at $736,000 after acquiring an additional 1,170 shares in the last quarter. Stevens Capital Management LP bought a new position in Edwards Lifesciences during the second quarter valued at approximately $1,542,000. CWM LLC raised its position in Edwards Lifesciences by 12.9% during the second quarter. CWM LLC now owns 1,237 shares of the medical research company’s stock valued at $229,000 after acquiring an additional 141 shares in the last quarter. Finally, Covenant Multifamily Offices LLC bought a new position in Edwards Lifesciences during the second quarter valued at approximately $556,000. Institutional investors and hedge funds own 82.43% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,369 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $216.26, for a total transaction of $1,161,099.94. Following the transaction, the vice president now owns 26,082 shares of the company’s stock, valued at $5,640,493.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 3,000 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $169.60, for a total transaction of $508,800.00. Following the transaction, the vice president now directly owns 20,674 shares in the company, valued at approximately $3,506,310.40. The disclosure for this sale can be found here. Insiders have sold 142,948 shares of company stock worth $27,936,332 in the last ninety days. 1.63% of the stock is currently owned by insiders.

A number of equities analysts have recently commented on the stock. BMO Capital Markets lifted their price target on shares of Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Wells Fargo & Co lifted their price target on shares of Edwards Lifesciences from $207.00 to $220.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Barclays lifted their price target on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research report on Wednesday, July 24th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Finally, Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the company an “overweight” rating in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $204.74.

EW stock traded up $2.11 on Thursday, reaching $215.62. 16,395 shares of the company were exchanged, compared to its average volume of 1,186,828. Edwards Lifesciences Corp has a 12 month low of $134.53 and a 12 month high of $219.71. The company has a fifty day simple moving average of $200.64. The stock has a market capitalization of $44.90 billion, a price-to-earnings ratio of 46.04, a PEG ratio of 2.72 and a beta of 0.87. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the firm posted $1.24 earnings per share. Edwards Lifesciences’s revenue was up 15.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: Quick Ratio

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.